For investors seeking momentum, Vanguard Russell 2000 ETF (VTWO - Free Report) is probably on radar. The fund just hit a 52-week high and is up 88% from its 52-week low of $76.92 per share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed.
VTWO in Focus
This fund targets the small-cap segment of the broad U.S. equity market with key holdings in healthcare, financials, industrials, consumer discretionary and technology. It charges 10 basis points in annual fees (see: all the Small-Cap Blend ETFs here).
Why the Move?
The small-cap corner of the broad U.S. stock market has been an area to watch lately given a vaccine development, which is being viewed as “a beginning to the end” of the coronavirus pandemic. Moderna (MRNA - Free Report) released preliminary data from its late-stage trials, which showed that its vaccine candidate was 94.5% effective against the coronavirus. The news was followed by promising late-stage trial results last week from the U.S. drugmaker Pfizer (PFE - Free Report) and German biotech firm BioNTech for their COVID-19 vaccine candidate. The data showed that the candidate was more than 90% effective in preventing the disease. The slew of positive data has instilled strong optimism into the economy which was hit-hard by the pandemic.
More Gains Ahead?
Currently, VTWO has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors seeking momentum, Vanguard Russell 2000 ETF (VTWO - Free Report) is probably on radar. The fund just hit a 52-week high and is up 88% from its 52-week low of $76.92 per share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed.
VTWO in Focus
This fund targets the small-cap segment of the broad U.S. equity market with key holdings in healthcare, financials, industrials, consumer discretionary and technology. It charges 10 basis points in annual fees (see: all the Small-Cap Blend ETFs here).
Why the Move?
The small-cap corner of the broad U.S. stock market has been an area to watch lately given a vaccine development, which is being viewed as “a beginning to the end” of the coronavirus pandemic. Moderna (MRNA - Free Report) released preliminary data from its late-stage trials, which showed that its vaccine candidate was 94.5% effective against the coronavirus. The news was followed by promising late-stage trial results last week from the U.S. drugmaker Pfizer (PFE - Free Report) and German biotech firm BioNTech for their COVID-19 vaccine candidate. The data showed that the candidate was more than 90% effective in preventing the disease. The slew of positive data has instilled strong optimism into the economy which was hit-hard by the pandemic.
More Gains Ahead?
Currently, VTWO has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PFE - FREE
Get the latest research report on MRNA - FREE
Get the latest research report on VTWO - FREE